Profile data is unavailable for this security.
About the company
Hansoh Pharmaceutical Group Company Ltd is an investment holding company primarily engaged in the research and development, production and sale of a series of pharmaceutical products. The Company’s innovative drug products include Ameile, Hansoh Xinfu, Mailingda, Fulaimei, Hengmu, XINYUE, Saint Luolai and other products. The Company’s drug products are mainly used in oncology, anti-infective diseases, central nervous system (CNS) diseases, metabolic diseases and other therapeutic areas. The Company mainly conducts its business in the domestic market.
- Revenue in HKD (TTM)14.92bn
- Net income in HKD5.41bn
- Incorporated2015
- Employees9.31k
- LocationHansoh Pharmaceutical Group Company Ltd287 Xiangke Road, Pudong New DistrictSHANGHAI 201210ChinaCHN
- Websitehttps://www.hspharm.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3SBio Inc | 10.27bn | 2.67bn | 59.95bn | 6.27k | 21.85 | 3.02 | 18.02 | 5.84 | 1.08 | 1.08 | 4.15 | 7.83 | 0.3799 | 1.54 | 6.97 | 1,840,692.00 | 10.46 | 7.95 | 15.09 | 10.32 | 85.37 | 83.73 | 27.54 | 22.68 | 2.12 | -- | 0.0899 | -- | 16.53 | 11.36 | 34.93 | 16.51 | 14.65 | -- |
| WuXi XDC Cayman Inc | 5.76bn | 1.50bn | 81.77bn | 2.27k | 56.25 | 9.29 | 49.59 | 14.21 | 1.16 | 1.16 | 4.43 | 7.00 | 0.5687 | 21.58 | 3.31 | 2,820,236.00 | 14.83 | -- | 19.71 | -- | 33.01 | -- | 26.08 | -- | 2.14 | -- | 0.1225 | -- | 90.80 | -- | 277.24 | -- | -- | -- |
| CSPC Pharmaceutical Group Ltd | 29.66bn | 4.59bn | 118.11bn | 19.27k | 25.54 | -- | 55.76 | 3.98 | 0.4013 | 0.4013 | 2.59 | -- | -- | -- | -- | 1,385,813.00 | -- | 14.64 | -- | 19.49 | 66.23 | 72.50 | 15.54 | 19.11 | -- | -- | -- | 41.10 | -7.76 | 5.59 | -26.31 | 3.11 | 4.76 | 21.28 |
| Sino Biopharmaceutical Ltd | 34.58bn | 4.41bn | 122.51bn | 23.06k | 26.72 | 3.09 | 13.33 | 3.54 | 0.2444 | 0.2427 | 1.91 | 2.11 | 0.4317 | 2.83 | 3.98 | 1,418,445.00 | 9.56 | 12.16 | 18.52 | 20.91 | 81.77 | 80.75 | 22.15 | 26.50 | 1.28 | -- | 0.2071 | 27.19 | 10.18 | 3.56 | 3.93 | -7.01 | -7.91 | 6.66 |
| Innovent Biologics Inc | 12.92bn | 1.28bn | 154.61bn | 6.19k | 116.70 | 9.03 | 84.39 | 11.96 | 0.7635 | 0.7635 | 7.77 | 9.87 | 0.5205 | 1.80 | 7.39 | 2,283,552.00 | 5.16 | -8.71 | 6.52 | -10.73 | 85.69 | 84.74 | 9.91 | -24.84 | 2.39 | -- | 0.1898 | -- | 51.82 | 55.17 | 90.79 | -- | 35.02 | -- |
| Hansoh Pharmaceutical Group Company Ltd | 14.92bn | 5.41bn | 223.44bn | 9.31k | 40.62 | 6.24 | 38.25 | 14.97 | 0.9084 | 0.9084 | 2.51 | 5.92 | 0.3952 | 1.93 | 4.68 | 1,659,887.00 | 14.33 | 11.36 | 16.01 | 13.27 | 90.84 | 90.68 | 36.25 | 30.80 | 8.38 | -- | 0.0037 | 28.12 | 21.35 | 7.15 | 33.39 | 11.33 | -5.71 | -- |
Data as of Feb 16 2026. Currency figures normalised to Hansoh Pharmaceutical Group Company Ltd's reporting currency: Hong Kong Dollar HKD
4.47%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 05 Feb 2026 | 46.91m | 0.78% |
| The Vanguard Group, Inc.as of 04 Feb 2026 | 44.18m | 0.73% |
| BlackRock Fund Advisorsas of 06 Feb 2026 | 32.52m | 0.54% |
| Strategic Advisers LLCas of 31 Dec 2025 | 27.46m | 0.45% |
| China Universal Asset Management Co., Ltd.as of 30 Jun 2025 | 27.44m | 0.45% |
| Fidelity Management & Research (Hong Kong) Ltd.as of 31 Dec 2025 | 20.75m | 0.34% |
| GF Fund Management Co., Ltd.as of 30 Jun 2025 | 20.51m | 0.34% |
| BlackRock Advisors (UK) Ltd.as of 06 Feb 2026 | 18.44m | 0.31% |
| UBS Asset Management (Hong Kong) Ltd.as of 31 Oct 2025 | 16.36m | 0.27% |
| FIL Investment Management (Hong Kong) Ltd.as of 31 Dec 2025 | 16.24m | 0.27% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
